Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 30 people, all of whom received a combination of two chemotherapy medicines — docetaxel and gemcitabine hydrochloride. The trial was looking at patients with a type of cancer affecting the ovaries or the peritoneum (the lining of the abdomen), and it set out to measure how often tumours responded to this drug combination, as well as how long participants went without their cancer getting worse. The reported data shows that 62% of participants had a measurable tumour response — meaning their tumours either disappeared completely or shrank significantly during treatment. This figure covers what are called "complete responses" (tumour no longer detectable) and "partial responses" (tumour shrank but did not disappear entirely). For the secondary outcome, the reported data shows that the median time without the cancer progressing (getting worse or spreading) was 7.2 months. The median is the middle value — meaning roughly half of participants reached that point sooner and half later. One participant did not complete the study, though the reason was not reported in the data provided. It is worth noting that this was a single group of 30 participants with no comparison group, so these numbers reflect only what was observed in this specific trial population. The trial did not report any safety or side-effect outcome data in the structured results submitted to ClinicalTrials.gov. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Ovarian Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with ovarian cancer or peritoneal cavity cancer that was confirmed by a tissue sample (biopsy)
- Your cancer came back or stopped responding after your first treatment, which must have included a platinum-based chemotherapy drug
- Your cancer may have either responded to platinum treatment initially (platinum-sensitive) or stopped responding within 6 months of finishing it (platinum-resistant)
- Your cancer can be measured or tracked — either through scans or through a blood marker called CA 125 that has risen significantly over time
- You are 18 years of age or older
- You are reasonably active and able to care for yourself (confirm with trial site)
- Your blood counts are at acceptable levels — including white blood cells, neutrophils, platelets, and hemoglobin
- Your liver is functioning within acceptable ranges, based on blood tests
- Your kidneys are functioning well enough, based on blood tests
- You have only received one prior chemotherapy treatment course for this cancer
- It has been at least 4 weeks since any previous radiotherapy and you have recovered from it
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You are pregnant, breastfeeding, or not willing to use effective contraception if you could become pregnant
- You have significant nerve damage or numbness/tingling in your hands or feet beyond a mild level
- You have been diagnosed with another cancer in the past 2 years (exceptions may apply for certain skin cancers or early-stage cervical changes — confirm with trial site)
- You have had a heart attack in the past 3 months
- You have heart failure or certain types of irregular heart rhythm
- You have previously had a severe allergic reaction to medications containing a substance called polysorbate 80 (an ingredient used in some drug formulations)
- You have previously received gemcitabine or docetaxel chemotherapy
- You have received more than one course of chemotherapy for this cancer
- You are currently taking part in another clinical trial or receiving any other experimental treatment for this cancer
- You are currently receiving any other treatment for this cancer at the same time
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Response Rate to the Combination of Gemcitabine and Docetaxel in Patients With Platinum Sensitive and Resistant Epithelial Ovarian or Peritoneal Cancer.
Other options
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.